Quantcast

Latest NmVac4-A/C/Y/W-135 Stories

2014-06-17 08:29:10

Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US(1) BASEL, Switzerland, June 17, 2014 /PRNewswire/ -- Novartis announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero(®) (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal...

2014-05-22 23:04:01

Report Identifies Challenges and Includes Recommendations for Management of Future Meningococcal Disease Outbreaks Bethesda, Maryland (PRWEB) May 22, 2014 An expert panel assembled by the National Foundation for Infectious Diseases (NFID) examined recent meningococcal disease outbreaks on multiple college campuses in the United States and concluded that despite its rarity, the severe nature of meningococcal disease makes advance planning essential. These outbreaks were particularly...

2014-05-09 08:25:36

ALBANY, New York, May 9, 2014 /PRNewswire/ -- According to a new report published by Transparency Market Research "Meningococcal Vaccines Market (Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from...

2014-02-26 08:28:23

DORVAL QC, Feb. 26, 2014 /CNW/ - Novartis announced today that Bexsero(®) (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection.(1) Bexsero(®) is the first broad-coverage vaccine to help protect against MenB...

2014-02-24 08:28:29

- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb. 24, 2014 /PRNewswire/ -- Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero(®) (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7....

2013-09-24 13:21:31

Clinical trial A study of 4CMenB, a new vaccine to protect against meningitis B bacteria (which can cause potentially fatal bacterial meningitis in children), shows that waning immunity induced by infant vaccination can be overcome by a booster dose at 40 months of age, according to a clinical trial published in CMAJ (Canadian Medical Association Journal). The 4CMenB vaccine, an important breakthrough in the fight against childhood meningitis, was recently licensed in Europe and is...

2013-09-13 08:19:19

No cases of serogroup A meningococcal meningitis following vaccination of almost 2 million people; incidence of all cases of meningitis reduced by 94 percent Evaluation of the effectiveness of a mass vaccination campaign with a new meningitis serogroup A vaccine, PsA-TT, in sub-Saharan Africa found that it had a dramatic impact on cases of serogroup meningitis and on carriage of the disease-causing bacteria in the throat, according to new research published in The Lancet. Authors from...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.